Free Trial

Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Nurix Therapeutics logo
$11.89 +0.37 (+3.25%)
As of 11:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Key Stats

Today's Range
$11.57
$12.16
50-Day Range
$9.51
$13.18
52-Week Range
$8.18
$29.56
Volume
182,880 shs
Average Volume
879,346 shs
Market Capitalization
$909.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.31
Consensus Rating
Moderate Buy

Company Overview

Nurix Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

NRIX MarketRank™: 

Nurix Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 525th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nurix Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nurix Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nurix Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nurix Therapeutics is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nurix Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nurix Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.93% of the float of Nurix Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Nurix Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nurix Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.93% of the float of Nurix Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.
  • News Sentiment

    Nurix Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.08 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    13 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,096.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of Nurix Therapeutics is held by insiders.

  • Read more about Nurix Therapeutics' insider trading history.
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Stock News Headlines

HC Wainwright Analysts Lift Earnings Estimates for NRIX
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
Nurix Therapeutics Climbs After 2Q Revenue Triples
See More Headlines

NRIX Stock Analysis - Frequently Asked Questions

Nurix Therapeutics' stock was trading at $18.84 at the beginning of the year. Since then, NRIX shares have decreased by 38.9% and is now trading at $11.52.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its earnings results on Wednesday, July, 9th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.27. The company had revenue of $44,056 billion for the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative trailing twelve-month return on equity of 45.26%.

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional investors of Nurix Therapeutics include KLP Kapitalforvaltning AS (0.02%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff.
View institutional ownership trends
.

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

Last Earnings
7/09/2025
Today
7/27/2025
Next Earnings (Estimated)
10/10/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRIX
CIK
1549595
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

High Price Target
$41.00
Low Price Target
$16.00
Potential Upside/Downside
+154.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$193.57 million
Net Margins
-234.57%
Pretax Margin
-233.61%
Return on Equity
-45.26%
Return on Assets
-34.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.82
Quick Ratio
6.82

Sales & Book Value

Annual Sales
$54.55 million
Price / Sales
16.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.44 per share
Price / Book
1.55

Miscellaneous

Outstanding Shares
76,450,000
Free Float
70,792,000
Market Cap
$880.70 million
Optionable
Optionable
Beta
2.15
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NRIX) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners